The clinical efficacy and safety of therapeutic glycoproteins are affected by the distribution, structure, and composition of their saccharide groups. The saccharide groups are usually heterogeneous due to changes in cell culture and other conditions during the manufacturing process. Therefore, the condition of glycosylation is considered a key quality attribute of therapeutic glycoproteins.

The glycoengineering expression platforms developed by CD BioGlyco are important strategies for improving the safety, consistency, and reduced immunogenicity of biological drugs. Our platforms allow the production of therapeutic glycoproteins such as mAbs with well-defined and uniform Fc glycoform. Our platforms have significant advantages, such as enhancing Fc effector functions, improving safety and batch-to-batch consistency, and reducing immunogenicity. They can also generate new antibody variants with a greatly enhaced ability to recruit immune cells.

Our team of experts has extensive expertise in the field of glycoengineering. They have assembled the most advanced technologies to provide customers with glycoengineered mammalian, Pichia pastoris, and plant cell expression systems and can also customize cell lines according to research needs. Our antibody experts can also provide you with an integrated solution for antibody glycoengineering, allowing the production of glycoproteins in both mammalian and non-mammalian cells in an economical and time-saving manner.

Fig 1. Glycoengineering content chart Fig 1. Glycoengineering content chart (Chiang, A.W.T.; et al. 2016)

Our Services

Advantages of Us

  • Efficient expression vector, optimized protein expression strategies
  • The reliable and stable manufacturing process
  • Minimal batch-to-batch variation
  • High stability and consistency of experimental results
  • Customize experimental programs according to research needs

CD BioGlyco has the world's leading protein and antibody glycoengineering technology platforms, and our professional scientific researchers can tailor solutions according to your needs. We hope to start the exploration of glycobiology with you.

Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.


  1. Chiang, A.W.T.; et al. Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology. Curr Opin Struct Biol. 2016, 40: 104-111
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.